Last reviewed · How we verify

NCT04161170

Digital Integrated Healthcare Platform in Patients With Type 2 Diabetes

Status unknown NA Last updated 18 January 2020
What this trial tests

NA trial testing Digital integrated healthcare platform in Type 2 Diabetes in 294 participants. Status unknown.

Timeline
20 November 2019
Primary endpoint
31 August 2021
31 December 2021

Quick facts

Lead sponsorSamsung Medical Center
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment294
Start date20 November 2019
Primary completion31 August 2021
Estimated completion31 December 2021
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Samsung Medical Center

Who can join

Adults 19 to 70, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this three multicenter clinical trial, investigators will study the efficacy of digital integrated healthcare platform and CGMS (continuous glucose monitoring system) on diabetes management in patients with Type 2 diabetes. The platform is based on monitoring and intervention by medical staff using AI (aritificial intelligence)-based diet management solution. The study group includes 3 groups; a total of 294 participants with 1:1:1 randomized allocation: Control group A (no intervention and conventional diabetes management with regular outpatiant clinic visit every 3 months), Interventional group B (applying digital integrated healthcare platform by themselves, no monitoring and intervention by medical staff), and Interventional group C (applying digital integrated healthcare platform based on monitoring and intervention by medical staff using AI-based diet management solution and applying CGMS). This parallel study will be conducted for 48 weeks.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Validation of the effectiveness of a digital integrated healthcare platform utilizing an AI-based dietary management solution and a real-time continuous glucose monitoring system for diabetes management: a randomized controlled trial.
    Park SW, Kim G, Hwang YC, Lee WJ, et al · · 2020 · cited 13× · PMID 32650771 · DOI 10.1186/s12911-020-01179-x

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

Other Samsung Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04161170.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing